Sign in
SANA Stock Price, Chart, Stats & News
Sana Biotechnology, Inc.
Save
Sana Biotechnology, Inc. (SANA) does not currently pay a dividend.
815.39M
Market cap
–
Current P/E
–
Forward P/E
SANA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -58.57% |
ROE | -141.99% |
D/E | 0.49x |
Interest coverage ratio | – |
SANA valuation
P/E | – |
P/S | – |
P/B | 4.36x |
P/CF | -4.88x |
P/FCF | -5.11x |
P/OCF | -4.88x |
PEG | -0.03x |
EV multiple | -4.00x |
About
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.
Similar securities
Based on sector and market capitalization
Report issue